製品番号: HY-181978

GIT1-IN-1

GIT1-IN-1 is an inhibitor of ARF GTPase-activating protein 1 (GIT1) with a K_D of 6.2 μM. GIT1-IN-1 induces apoptosis (apoptosis) in liver and colon cancer cells, arrests the cell cycle at the G2/M phase, and inhibits cell proliferation, colony formation and migration. GIT1-IN-1 inhibits the activities of MEK and ERK, reduces the expression level of cyclin D1, and stabilizes cyclin B1 protein in liver and colon cancer cells. GIT1-IN-1 can be used in the research of liver cancer and colon cancer.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 844464-54-6
分子式: C₂₁H₂₀N₄O₄S
分子量:424.47

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

GIT1-IN-1 構造式

CAS 番号: 844464-54-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
純度とドキュメンテーション
参考文献
Calculators
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

ERK1

ERK2

MEK1

MEK2

CDK1/cyclinB1

Ras アイソフォーム固有の製品をすべて表示 :

MEK アイソフォーム固有の製品をすべて表示 :

ERK アイソフォーム固有の製品をすべて表示 :

CDK アイソフォーム固有の製品をすべて表示 :

体外実験

GIT1-IN-1 (Compound C3) (10-100 μM; 24 h) inhibits viability and proliferation of HepG2, Hep3B, MzChA-1, HT-29, and RKO liver and colon cancer cells with an IC₅₀ of around 20 μM, but does not affect non-malignant AML12, HEK293, or primary mouse or human hepatocytes at concentrations up to 100 μM^[1].
GIT1-IN-1 (1-5 μM; 24 h) induces dose-dependent G2/M phase arrest in HepG2 and RKO liver and colon cancer cells, but does not affect cell cycle progression in non-malignant AML12 or HEK293 cells^[1].
GIT1-IN-1 (5 μM; 24-48 h) induces time-dependent apoptosis in RKO colon cancer cells and increases apoptosis and necrosis in HepG2 liver cancer cells after 48 hours, but does not induce cell death in non-malignant AML12, HEK293, or primary mouse or human hepatocytes^[1].
GIT1-IN-1 (1-10 μM; 24 h) inhibits clonogenic potential of HepG2 liver cancer cells and RKO colon cancer cells in a dose-dependent manner, but does not affect non-malignant AML12 cells^[1].
GIT1-IN-1 (1-2 μM; 24 h) inhibits migration of RKO colon cancer cells and MzChA-1 liver cancer cells in a dose-dependent manner^[1].
GIT1-IN-1 (5-10 μM; 24 h) at 10 μM disrupts GIT1-MAT2B and MEK1/2-cRAF/BRAF/ERK1/2/GIT1 interactions, and at 5 μM disrupts GIT1-CDC20, GIT1-APC3, cyclin B1-CDC20, and cyclin B1-APC3 interactions while enhancing GIT1-cyclin B1 interactions in HepG2 and RKO liver and colon cancer cells^[1].
GIT1-IN-1 (2-10 μM; 24 h) inhibits MEK and ERK pathway activity, as measured by reduced pMEK1/2, pERK1/2, and cyclin D1 levels, in HepG2, RKO, and MC38 liver and colon cancer cells, but does not affect pathway activity in non-malignant AML12 cells^[1].
GIT1-IN-1 (2-5 μM; 24 h) increases cyclin B1 protein stability, cyclin B1-CDK1 complex formation, and CDK1 activity in HepG2 and RKO liver and colon cancer cells, as indicated by a prolonged cyclin B1 half-life, reduced inhibitory CDK1 phosphorylation, and increased activating cyclin B1 phosphorylation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HepG2, Hep3B, MzChA-1, HT-29, RKO, AML12, HEK293, primary mouse hepatocytes, primary human hepatocytes
Concentration:

10 μM; 50 μM; 100 μM
Incubation Time:

24 h
Result:

Inhibited growth of HepG2, Hep3B, MzChA-1, HT-29, and RKO cells at 10 μM.
Exhibited dose-dependent reduction in viability and proliferation of cancer cells at 10, 50, and 100 μM.
Exerted dose-dependent inhibition of cancer cell viability with an IC₅₀ of around 20 μM.
Did not reduce viability or proliferation in AML12, HEK293, primary mouse hepatocytes, or primary human hepatocytes at concentrations up to 100 μM.

Cell Cycle Analysis^[1]

Cell Line:

HepG2, RKO, AML12, HEK293
Concentration:

1 μM; 2 μM; 5 μM
Incubation Time:

24 h
Result:

Reduced the percentage of HepG2 and RKO cells in the G1 phase.
Significantly increased the percentage of HepG2 and RKO cells in the G2/M phase, indicating G2/M phase arrest.
Induced dose-dependent G2/M phase arrest in HepG2 and RKO cells at concentrations from 1 to 5 μM.
Caused no G2/M arrest in AML12 or HEK293 cells.

Apoptosis Analysis^[1]

Cell Line:

HepG2, RKO, AML12, HEK293, primary mouse hepatocytes, primary human hepatocytes
Concentration:

5 μM
Incubation Time:

24 h; 48 h
Result:

Induced significant time-dependent apoptosis in RKO cells.
Increased apoptosis and necrosis significantly in HepG2 cells after 48 hours of treatment, though absolute values remained low.
Caused no increase in apoptosis or necrosis in AML12, HEK293, primary mouse hepatocytes, or primary human hepatocytes after 48 hours of treatment.

Cell Migration Assay^[1]

Cell Line:

RKO, MzChA-1
Concentration:

1 μM; 2 μM
Incubation Time:

24 h
Result:

Induced dose-dependent inhibition of cell migration in both RKO and MzChA-1 cells at 1 and 2 μM, measured as reduced scratch closure relative to baseline.

Western Blot Analysis^[1]

Cell Line:

HepG2, RKO
Concentration:

5 μM; 10 μM
Incubation Time:

24 h
Result:

Reduced the interaction between GIT1 and MAT2B in HepG2 cells at 10 μM.
Reduced recruitment of cRAF, BRAF, ERK1/2, and GIT1 to MEK1/2 in HepG2 and RKO cells at 10 μM.
Reduced interactions between GIT1 and CDC20, GIT1 and APC3, cyclin B1 and CDC20, and cyclin B1 and APC3 in HepG2 and RKO cells at 5 μM.
Enhanced the interaction between GIT1 and cyclin B1 in HepG2 cells at 5 μM.

Western Blot Analysis^[1]

Cell Line:

HepG2, RKO, MC38, AML12
Concentration:

2 μM; 3 μM; 5 μM; 10 μM
Incubation Time:

24 h
Result:

Reduced phosphorylated MEK1/2 (pMEK1/2) levels in HepG2 and RKO cells at 2, 3, and 5 μM.
Reduced phosphorylated ERK1/2 (pERK1/2) and cyclin D1 levels in HepG2 and MC38 cells at 10 μM.
Caused no effect on pMEK1/2, pERK1/2, or cyclin D1 levels in AML12 cells.

Western Blot Analysis^[1]

Cell Line:

HepG2, RKO, MC38
Concentration:

2 μM; 3 μM; 5 μM
Incubation Time:

24 h; 0, 1, 2, 4, 6 h (with CHX pretreatment)
Result:

Caused dose-dependent increase in cyclin B1 protein levels in HepG2 cells at 2, 3, and 5 μM.
Induced slight increase in cyclin B1 mRNA level (≤ 30%) and significant stabilization of cyclin B1 protein in HepG2 cells, prolonging the half-life of cyclin B1 from 3.6 h to > 24 h.
Increased formation of the cyclin B1-CDK1 complex in HepG2 and RKO cells.
Reduced inhibitory phosphorylation of CDK1 (p-Thr14/p-Tyr15) in HepG2 and MC38 cells.
Increased activating phosphorylation of cyclin B1 (p-S116) in HepG2 cells.

体内実験

GIT1-IN-1 (Compound C3) (100 μM; intratumoral; every other day; 6 days) significantly inhibits subcutaneous murine colorectal cancer growth, reduces tumor cell proliferation, and increases apoptosis by suppressing MEK activity in C57BL/6 mice^[1].
GIT1-IN-1 (25 mg/kg; intraperitoneal; daily; 5 days) significantly inhibits the growth of intrahepatic human colorectal cancer xenografts in nude mice^[1].
GIT1-IN-1 (15-20 mg/kg; intraperitoneal; intermittent dosing) significantly inhibits colorectal cancer liver metastasis in immune-competent C57BL/6 mice without causing measurable hepatic toxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (both sexes)^[1]
Dosage:

100 μM
Administration:

intratumoral; every other day; 6 days
Result:

Reduced tumor volume significantly compared to DMSO control.
Increased apoptotic cells significantly (TUNEL staining).
Reduced proliferation score significantly (PCNA staining).
Decreased phosphorylated MEK1/2 (Ser218/222) activity significantly relative to total MEK1/2, while GIT1 protein levels remained unchanged.
Changed MC38 tumor cells from spindle-shaped to small round cells (histological analysis).

Animal Model:

Nude (male, 4 months old)^[1]
Dosage:

25 mg/kg
Administration:

intraperitoneal; daily; 5 days
Result:

Reduced liver tumor bioluminescent intensity significantly relative to baseline and DMSO control.
Reduced tumor burden compared to DMSO-treated mice (gross liver examination).

Animal Model:

C57BL/6 (both sexes)^[1]
Dosage:

20 mg/kg (day 1); 15 mg/kg (daily for 3 days, then daily for 2 days after 2-day rest)
Administration:

intraperitoneal; intermittent dosing (20 mg/kg day 1, then 15 mg/kg daily ×3, 2-day rest, 15 mg/kg daily ×2)
Result:

Reduced bioluminescent intensity significantly relative to DMSO control, indicating inhibited liver tumor growth and metastasis.
Showed no significant difference in plasma ALT and AST levels compared to DMSO control, indicating no overt hepatic toxicity.
Reduced tumor burden compared to DMSO-treated mice (histological analysis).

化学情報

CAS 番号 844464-54-6
分子量 424.47
分子式 C₂₁H₂₀N₄O₄S
SMILES

O=C(CN1C(C(SC2=C3C=C4C(CC(C)(C)OC4)=N2)=C3N=C1)=O)NCC5=CC=CO5
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Peng H, et al. A small molecule inhibitor of ARF GTPase protein 1 limits liver and colon cancer cell growth and metastasis. Cell Death Dis. 2026;17(1):238. Published 2026 Feb 20. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

GIT1-IN-1

Ras アイソフォーム固有の製品をすべて表示

MEK アイソフォーム固有の製品をすべて表示

ERK アイソフォーム固有の製品をすべて表示

CDK アイソフォーム固有の製品をすべて表示

生物活性

化学情報

純度とドキュメンテーション

参考文献

Calculators

Help & FAQs

GIT1-IN-1 関連分類

HY-181978 関連分類